Bull case
Perspective Therapeutics is viewed favorably because its proprietary 212Pb alpha-emitting platform targets multiple high-value oncology settings, including neuroendocrine tumors, metastatic melanoma, and advanced solid tumors, while also creating scarcity value that could attract larger pharma partners seeking an in-house radiopharmaceutical capability. The investment case is further supported by upcoming clinical and operational catalysts, with bamzireotide navoxetan’s pivotal site activation around YE26, VMT01 data expected in late ’26, and a manufacturing network that is expanding to four regional sites by YE27 to strengthen long-term supply reliability. Fundamentally, the company also appears insulated from recent NRC patient-release concerns because DG-8070 explicitly excludes alpha emitters such as Pb-212, while Lutathera’s $225M in 2Q26 revenue and ~$900M FY26E sales provide positive commercial readthrough for the category.